Cancer reports最新文献

{"title":"Psychological Resilience and Associated Factors in Cancer Patients: A Cross-Sectional Analysis","authors":"Marta Esteban Blanco,&nbsp;Inmaculada Martinez de la Viuda,&nbsp;Maria Gemma Rodriguez Chico,&nbsp;Maria del Mar Félix Montalvo,&nbsp;Aurea Garcia Salas,&nbsp;Andrés Garcia Palomo,&nbsp;Maria Teresa Quintana Asenjo","doi":"10.1002/cnr2.70415","DOIUrl":"10.1002/cnr2.70415","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cancer remains one of the leading global health problems, with treatments that can compromise patients' quality of life.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to determine the prevalence and characteristics of resilience in cancer patients and to analyze the influence of psychological and social factors on disease perception.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>An analytical cross-sectional study was conducted between April and August 2023 including 61 cancer patients under treatment. Resilience was assessed with the RS-14, anxiety and depression with HADS (Hospital Anxiety and Depression Scale), and family functioning with the Family Apgar (Adaptation, Partnership, Growth, Affection, Resolve questionnaire). Sociodemographic and clinical data were obtained through structured questionnaires. Continuous variables were tested with Shapiro–Wilk and Levene's tests; descriptive statistics, t-tests, Mann–Whitney U, Chi-square were applied. Binary logistic regression examined resilience predictors, adjusting for confounders (BMI, employment status, surgery). Statistical significance was defined as <i>p</i> ⟨ 0.05. Participants were 50.8% women, aged 35–82 years. Cancer types included breast (18%), lung (29.5%), colon (9.8%), pancreas (11.5%), renal (1.6%), and others (29.5%). 11.5% had not received oncological treatment, while 93.4% underwent surgery. Most were non-smokers (82%) and retired (57.4%). Main comorbidities were respiratory (24.6%) and cardiovascular (23%). In surveys, 54.1% reported family members with cancer and 36.1% noted a lack of free time affected quality of life. Mean scores: resilience 69.3 (SD = 22.1), anxiety 10.3 (SD = 3.2), depression 11.6 (SD = 2.2), Apgar 17.1 (SD = 3.7). Logistic regression identified Apgar as the only significant predictor of resilience (OR = 0.294, 95% CI 0.113–0.761, <i>p</i> = 0.012), with higher family functioning linked to lower resilience. Model accuracy was 81.1% overall, 90.9% for resilient, and 65.0% for non-resilient patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Social, clinical, and family situations all have an impact on cancer patients' resilience. In order to maximize resilience and quality of life, family functioning appears as a contradictory component, indicating the necessity of psychological, family-centered, and interdisciplinary interventions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70415","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145888313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Different Neoadjuvant Treatment Regimens in Locally Advanced Squamous Head and Neck Cancer.","authors":"Ya-Ting Ding, Bin-Bin Fang, Lian-Bing Zhu, Ke-Jin Qiu, Li-Li Yang, Hui Ye, Yun-Xia Lv, Geng-Ming Cai","doi":"10.1002/cnr2.70447","DOIUrl":"10.1002/cnr2.70447","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Head and neck squamous cell carcinoma (HNSCC), which constitutes approximately 90% of all head and neck cancers, represents a significant global health burden. A concerning trend is the rising incidence, particularly among younger populations, which has been partly attributed to human papillomavirus (HPV) infection. While treatment outcomes are favorable for early-stage disease, approximately 60% of patients are diagnosed with locally advanced HNSCC (LA-HNSCC), for whom prognosis remains suboptimal. Induction chemotherapy, such as the TPF regimen, is often used to reduce tumor burden but is limited by substantial toxicity. Currently, no global consensus exists on the optimal neoadjuvant approach for LA-HNSCC. This network meta-analysis aims to comprehensively compare the efficacy and safety of available neoadjuvant therapies for LA-HNSCC, excluding nasopharyngeal carcinoma due to distinct treatment paradigms, in order to inform clinical decision-making.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;To compare the efficacy and safety of different neoadjuvant treatment options in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods and results: &lt;/strong&gt;We conducted a comprehensive literature search across four major databases (PubMed, Web of Science [WOS], Embase, and Cochrane Library) from their inception through August 2024. The primary outcome measures included objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and serious adverse events (SAEs). This analysis included 23 studies (19 randomized controlled trials [RCTs] and 4 non-randomized studies [NRS]) involving 4052 patients. Network meta-analysis (NMA) revealed the following findings: Regarding efficacy, hyperthermia + chemotherapy demonstrated superior outcomes in both ORR and OS, followed by immunotherapy + chemotherapy. Hyperthermia + chemotherapy showed significantly better ORR compared to targeted therapy + chemotherapy, TP, PF, T, and single-agent immunotherapy (p &lt; 0.05). Similarly, immunotherapy + chemotherapy outperformed all other therapies except hyperthermia + chemotherapy in ORR (p &lt; 0.05). For OS, both hyperthermia + chemotherapy and TPF were significantly more effective than PF and TP (p &lt; 0.05). In PFS, immunotherapy + chemotherapy showed the best results, followed by targeted therapy + chemotherapy, with immunotherapy + chemotherapy being significantly superior to PF (p &lt; 0.05). Regarding safety, hyperthermia + chemotherapy showed the poorest safety profile, followed by TPF. Specifically, T and TP demonstrated significantly better safety than hyperthermia + Chemotherapyy (p &lt; 0.05).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;In the neoadjuvant treatment of LA-HNSCC, both hyperthermia + chemotherapy and immunotherapy + chemotherapy regimens have demonstrated promising therapeutic efficacy; however, their safety profiles require further comprehensive evaluation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Trial registration: &lt;/st","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 1","pages":"e70447"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12835624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146050448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EGFR p.V774M/p. the S768I Compound Mutation in NSCLC Is a Good Prognostic Marker for IPHC- and Furmonertinib-Based Treatment: A Case Report","authors":"Yanan Wang,&nbsp;Guanying Ren,&nbsp;Zizheng Song,&nbsp;Ling Hu,&nbsp;Weiqi Li,&nbsp;Xiaolei Wang","doi":"10.1002/cnr2.70444","DOIUrl":"10.1002/cnr2.70444","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Intrapleural perfusion hyperthermic chemotherapy (IPHC) can be used to select specific lung cancer cells of a certain genotype. Some genetic mutations, especially epidermal growth factor receptor (EGFR) mutations, are potential markers for EGFR or other targeted therapies. Here, we report a unique case of a patient with EGFR p.V774M/p. S768I mutations that were associated with prolonged stable disease after treatment with IHPC, especially following furmonertinib-based treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>A 47-year-old Chinese female patient was admitted to a regional cancer hospital and presented with malignant pleural effusion (MPE). The TNM and clinical stages were identified as T2aN2M1c and IVB, respectively. The TPS value is 40%. IHP combined with chemotherapy was then carried out to remove MPE. For first-stage treatment, three cycles of afatinib-based adjuvant chemotherapy beginning in September 2022 were given, and the degree of pleural effusion on the left side of the chest was not reduced. The best response (BOR) assessment of the local lesion was a partial response (PR). Furmonertinib-based adjuvant monotherapy was performed from May 2023 to July 2024. The BOR evaluation results during the monotherapy courses were all judged as SD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The EGFR p.V774M/p.The S768I mutation contributed to improving the efficiency of furmonertinib-based therapy for NSCLC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70444","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Sleep Disorders and Quality of Life in Patients With Mycosis Fungoides","authors":"Seyed AmirReza Mohammadi,&nbsp;Mozhdeh Sepaskhah,&nbsp;Arvin Hedayati,&nbsp;Ladan Dastgheib,&nbsp;Soheila Khodakarim,&nbsp;Mohammad Amin Gholami","doi":"10.1002/cnr2.70421","DOIUrl":"10.1002/cnr2.70421","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma, presenting with variable clinical features that can be pruritic. Pruritus and the overall disease burden may disrupt sleep and diminish quality of life; yet, sleep disturbances in MF remain under-investigated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To evaluate sleep quality and quality of life in MF patients compared with healthy controls.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>In a cross-sectional, case–control study at a referral clinic in Shiraz, Iran, 78 MF patients (TNMB stages IA–IIIA) and 76 age- and sex-matched controls completed the Pittsburgh Sleep Quality Index (PSQI), the 12-Item Short Form Survey (SF-12), and the Hospital Anxiety and Depression Scale (HADS). MF patients had significantly poorer sleep quality, with 62.8% reporting poor sleep quality compared to 27.6% of controls (<i>p</i> &lt; 0.001). Among MF patients, poorer sleep quality was significantly associated with greater pruritus intensity, more advanced disease stage, and a higher modified severity-weighted assessment tool score (mSWAT) (all <i>p</i> &lt; 0.05). In contrast, histopathological subtype and treatment modality showed no significant association. MF patients exhibited higher rates of moderate-to-severe anxiety (34.6% vs. 15.8%) and depression (30.7% vs. 14.6%) (<i>p</i> &lt; 0.05). Physical health scores on the SF-12 were significantly lower in the MF group (<i>p</i> &lt; 0.01), whereas the decrease in mental health scores did not reach significance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>MF is associated with significant sleep dysfunction, psychological distress, and impaired physical quality of life. Pruritus intensity, disease stage, and cutaneous disease burden are key contributors to poor sleep quality. Larger studies are warranted to further elucidate the extent and mechanisms of sleep disturbance in this population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12745892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Potential Ferroptosis Biomarkers in Multiple Myeloma via WGCNA and Experiments","authors":"Yifan Wang,&nbsp;Xing Xie,&nbsp;Mengyuan Gu,&nbsp;Yanting Zheng,&nbsp;Jing Wu,&nbsp;Qicai Wang,&nbsp;Zhian Ling,&nbsp;Ruolin Li","doi":"10.1002/cnr2.70446","DOIUrl":"10.1002/cnr2.70446","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Multiple myeloma is a common malignant tumor of the hematologic system, and genetic alterations play a crucial role in its occurrence and development. Ferroptosis is an oxidative and iron-dependent programmed cell death, which has a strong correlation with tumor development. This study aimed to identify potential diagnostic ferroptosis-related genes of MM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>MM datasets were screened from the GEO database using publicly available transcriptomic data. Ferroptosis-related hub genes were identified through enrichment analysis, WGCNA, and machine learning algorithms. ROC curves, boxplots, RT-qPCR, and ELISA were conducted to validate the expression levels of these hub genes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 178 ferroptosis-related DEGs were identified, including 114 up-regulated genes and 64 down-regulated genes. Enrichment analysis indicated that the DEGs were primarily associated with stress, autophagy, and metabolism. According to the WGCNA, the brown module has the highest correlation with clinical symptoms, containing 1141 DEGs. Combining with the identified ferroptosis-related DEGs, two hub genes of CDKN1A and BCAT2 were identified by multiple bioinformatics techniques of LASSO, SVM, and Random Forest. ROC curves demonstrated strong diagnostic values in CDKN1A (test set, AUC = 0.881; validation set, AUC = 0.705) and <i>BCAT2</i> (test set, AUC = 0.808; validation set, AUC = 0.756). RT-qPCR confirmed that the mRNA expression levels of CDKN1A and BCAT2 in three MM cells (RPMI 8226, WT-U266, and LP-1) were both significantly higher than the control HMy2.CIR cell line (<i>p</i> &lt; 0.05). ELISA quantification revealed significantly elevated relative expression of CDKN1A protein in the MM cohort compared to healthy controls (<i>p</i> &lt; 0.01), but the protein expression of BCAT2 exhibited comparable levels <i>(p</i> &gt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our results suggest that CDKN1A and BCAT2 are potential ferroptosis-related biomarkers for MM. This may help understand the molecular mechanisms and therapeutic strategies of MM.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12745893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Downregulation of TNFAIP3 Associated With Poor Prognosis and Immune Response in Breast Cancer","authors":"Yeqin Wu,&nbsp;Zhaoyang Qin,&nbsp;Gangping Wang","doi":"10.1002/cnr2.70443","DOIUrl":"10.1002/cnr2.70443","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast cancer (BRCA) progression is closely linked to dysregulated inflammatory processes within the tumor microenvironment (TME). TNFAIP3, a key regulator of TNF-α signaling, plays a dual role in cancer biology, but its precise function in BRCA pathogenesis and immune modulation remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to elucidate the clinical significance, immune regulatory role, and molecular mechanisms of TNFAIP3 in BRCA progression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>We conducted an analysis of RNA-seq data from 1113 BRCA samples and 113 normal samples sourced from TCGA, along with protein data from 125 BRCA samples and 18 normal samples obtained from the CPTAC database. Comprehensive analyses included: (1) differential expression across cancer types and BRCA subtypes; (2) correlation with clinicopathological features; (3) survival analysis using Kaplan–Meier and Cox regression; (4) immune cell infiltration assessment via ssGSEA; and (5) co-expression analysis of TNFAIP3-LINC01096. TNFAIP3 was significantly downregulated in BRCA (<i>p</i> &lt; 0.001) and associated with aggressive features, including advanced TNM stage (T4 vs. T1, <i>p</i> = 0.021) and poor prognosis (HR = 1.48, <i>p</i> = 0.035). Immune profiling revealed strong correlations with cytotoxic T cells (<i>ρ</i> = 0.632) and dendritic cells (<i>ρ</i> = 0.602). A novel TNFAIP3-LINC01096 regulatory network was identified (<i>ρ</i> = 0.582, <i>p</i> &lt; 0.001), potentially mediated by shared miR-3130-3p binding sites.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our findings suggest a role of TNFAIP3 as a critical regulator of BRCA progression and tumor immunity. The TNFAIP3-LINC01096 axis represents a promising therapeutic target, particularly for immunotherapy-resistant cases. These results provide a rationale for developing TNFAIP3-based prognostic tools and immunomodulatory strategies in BRCA management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12747788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145854739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venetoclax-Based Therapy for Early Relapse in Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Minireview","authors":"Yufeng Du,&nbsp;Mohammad Arian Hassani,&nbsp;Chunhong Li,&nbsp;Zhijia Zhao,&nbsp;Yikun Liu,&nbsp;Chengtao Zhang,&nbsp;Jinsong Yan","doi":"10.1002/cnr2.70450","DOIUrl":"10.1002/cnr2.70450","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Refractory/relapsed acute myeloid leukemia (R/R-AML) typically exhibits resistance to conventional chemotherapy, resulting in a poor overall therapeutic outcome. Salvage allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the primary treatment option in such patients. However, posttransplant relapse is still a challenge, with no established effective regimens.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>In this case report, we present the case of a 40-year-old male diagnosed with R/R-AML who underwent salvage allo-HSCT. Unfortunately, after 4 months of follow-up, a relapse occurred. We modified the immunosuppressive therapy and administered donor lymphocyte infusion (DLI) and decitabine but failed to obtain complete remission (CR). Subsequently, a combination of venetoclax (Ven) and azacitidine (Aza), followed by the DLI regimen, was initiated. The patient achieved CR with no measurable residual disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our data suggest that the administration of Ven in combination with Aza followed by the DLI regimen used for early post-HSCT relapsed AML could serve as a valuable reference for treating similar patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12747801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145853887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of RANBP3L in Pan-Cancer With Its Significance in Hepatocellular Carcinoma","authors":"Beini Cen,&nbsp;Jie Li,&nbsp;Chao Wang","doi":"10.1002/cnr2.70440","DOIUrl":"10.1002/cnr2.70440","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>RAN binding protein 3-like (RANBP3L), a member of the Ran-binding protein family, has been linked to various cellular functions, but the role in cancer remains underexplored. In this research, we assessed the diagnostic and prognostic value of RANBP3L in pan-cancer, especially in liver hepatocellular carcinoma (LIHC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to explore the pan-cancer expression, prognostic value, and immune-related roles of RANBP3L, especially emphasis on validating its diagnostic and prognostic significance in hepatocellular carcinoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We analyzed RANBP3L expression of 33 cancer types from TCGA data and assessed its relationship with overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI). We used TIMER2.0 and CIBERSORT to explore the correlation between RANBP3L expression and immune cells. We conducted immunohistochemistry, qRT-PCR, and western blotting by using tissue samples from LIHC patients to assess the RANBP3L's diagnostic and prognostic value of LIHC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In 18 different cancers, RANBP3L expression was found to be lower in tumor tissues compared to normal tissues, including LIHC. Lower RANBP3L expression was related to shorter OS, DSS, and PFI in LIHC. ROC analysis and the nomogram model based on RANBP3L expression demonstrated high predictive accuracy for patient diagnosis and survival. Moreover, immune infiltration analysis showed that RANBP3L was related to various immune cells and impacted prognosis. Furthermore, analysis of LIHC patient tissues found that higher RANBP3L expression was related to better tumor-free survival and OS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>RANBP3L plays a crucial role in LIHC. Not only does its expression level correlate with patient survival, but it also plays an important role in immune modulation. RANBP3L presents a promising candidate for future therapeutic strategies and a biomarker for LIHC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12745881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunoinformatics-Based Multi-Epitope Vaccine Targeting Helicobacter Pylori","authors":"Aytak Vahdat Khajeh Pasha,&nbsp;Mohammad Esfandiyari,&nbsp;Alireza Parnian,&nbsp;Mohammad Mahboubi-Rabbani,&nbsp;Maryam Bayanati","doi":"10.1002/cnr2.70441","DOIUrl":"10.1002/cnr2.70441","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The rising global incidence of <i>Helicobacter pylori</i>-related diseases, particularly gastric cancer, underscores the urgent need for effective preventive vaccines, motivating the exploration of innovative immunoinformatic strategies to address this public health challenge.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The aim of this study was to design a multi-epitope subunit vaccine for Helicobacter pylori using an immunoinformatics approach. Specifically, the objectives were to predict potential epitopes from the flagellin B and urease B proteins, integrate the cholera toxin B subunit (CTB) as a mucosal adjuvant, and perform computational validation of the vaccine construct for antigenicity, stability, and interaction with immune receptors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study utilized an immunoinformatics approach to design a multi-epitope subunit vaccine, involving epitope prediction from flagellin B and urease B, integration of the cholera toxin B subunit (CTB) as a mucosal adjuvant, and computational validation through tools like VaxiJen, Phyre2, MolProbity, and HDOCK for antigenicity, structure, and docking analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The resulting vaccine construct comprises 406 amino acids with a molecular weight of 43 424.77 Da, exhibiting a predicted antigenic score of 1.0084, non-allergenic and non-toxic properties, and a stable physiochemical profile (instability index 23.51, GRAVY −0.425). Structural analysis suggested 99.1% (525/530) of residues in favored Ramachandran regions and 100.0% in allowed regions. Molecular docking with Toll-like receptor 5 (TLR5) indicated a superior docking score of −309.05 and a confidence score of 0.9601, outperforming TLR2 (−250.74), with 10 CTL epitopes (6 from flagellin B, 4 from urease B), 6 HTL epitopes, and 2 LBL epitopes linked by AAY, GPGPG, and KK linkers, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This research provides a computationally optimized vaccine design that shows potential for eliciting immune responses against <i>H. pylori</i>. Importantly, the findings remain entirely theoretical and require rigorous experimental validation in vitro and in vivo to assess their immunological relevance, safety, and efficacy before any translational or clinical application can be considered.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12745834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhanced Diagnosis of Lung and Colon Cancer Severity Through Deep Feature Analysis Using DenseNet201 and SVM With Histopathological Images: A Super-Resolution Approach","authors":"Pragati Patharia,&nbsp;B. Surya Prasad Rao,&nbsp;Prabira Kumar Sethy,&nbsp;Ashoka Kumar Ratha,&nbsp;Aziz Nanthaamornphong","doi":"10.1002/cnr2.70439","DOIUrl":"10.1002/cnr2.70439","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aim</h3>\u0000 \u0000 <p>The worldwide healthcare system faces significant challenges due to the increasing prevalence of lung and colon cancer, highlighting the need for timely and accurate detection to improve patient prognosis. The precision of cancer diagnosis is highly dependent on the expertise of histopathologists, making it a complex and demanding endeavor. A shortage of sufficiently skilled experts can lead to the ineffective allocation of healthcare resources, potential misdiagnoses, and unwarranted interventions, ultimately threatening patient well-being. However, technological advancements have introduced deep learning as a powerful tool in clinical applications, particularly in the field of medical imaging. This study aims to develop a novel diagnostic method leveraging deep learning techniques to enhance the accuracy of lung and colon cancer detection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The study utilized the LC25000 dataset, which comprises 25 000 histopathological images of lung and colon tissue. A novel approach was implemented using a Fast Super-Resolution Convolutional Neural Network (FSRCNN) for image enhancement and a Support Vector Machine (SVM) model based on DenseNet201 for classification. The FSRCNN was employed to improve the clarity and detail of images by increasing their resolution, which is crucial for accurate cancer detection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The proposed model demonstrated superior performance compared to existing Convolutional Neural Network (CNN) models. It achieved an overall accuracy of 98.00%, precision of 98.10%, sensitivity of 98%, F1 score of 0.98, and specificity of 99.50%. These metrics indicate a significant enhancement in diagnostic accuracy and reliability, underscoring the effectiveness of the FSRCNN and SVM-based DenseNet201 model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The implementation of the FSRCNN and SVM-based DenseNet201 model provided substantial improvements in the detection of lung and colon cancer, as evidenced by high accuracy and specificity metrics. While the LC25000 dataset offered a solid foundation for this analysis, future research should aim to validate the model's effectiveness using a broader array of diverse and extensive datasets. Additionally, integrating supplementary diagnostic techniques, such as genetic data and electronic health records, could further enhance the model's diagnostic precision and practical application in cancer diagnosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12724475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145809581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}